<DOC>
	<DOCNO>NCT00761644</DOCNO>
	<brief_summary>The goal clinical research study learn high safe dos combination Doxil ( liposomal doxorubicin ) , Avastin ( bevacizumab ) , Torisel ( Temsirolimus ) give patient advanced cancer spread unable surgically remove . The safety effectiveness combination drug also study .</brief_summary>
	<brief_title>Doxil , Bevacizumab Temsirolimus Trial</brief_title>
	<detailed_description>The Study Drugs : Liposomal doxorubicin design cause cancer cell fragile , may cause cancer cell die . Bevacizumab design block slow growth cancer cell block growth blood vessel supply nutrient tumor growth . Temsirolimus design block growth cancer cell , may eventually cause cancer cell die . Everolimus design block protein call mammilian target rapamycin ( mTOR ) inside cancer cell , involved cancer cell growth . Study Groups : If find eligible take part study , assign fix dose level combination liposomal doxorubicin , bevacizumab , either temsirolimus everolimus , base join study . Up 9 dose level study drug combination test . Three ( 3 ) participant enrol dose level . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose study drug combination find . Study Drug Administration : Liposomal doxorubicin , bevacizumab , either temsirolimus everolimus give `` cycle . '' Cycles 21 day ( long , depend side effect may experience ) . Liposomal doxorubicin give vein Day 1 cycle . On Day 1 Cycle 1 , receive 3 hour . If tolerate well Cycle 1 , receive 60 minute Cycle 2 . If tolerate well Cycle 2 , receive 60 minute cycle . Bevacizumab give vein Day 1 cycle . On Day 1 Cycle 1 , receive 90 minute . If tolerate well Cycle 1 , receive 60 minute Cycle 2 . If tolerate well Cycle 2 , receive 30 minute Cycle 3 . It continue give 30 minute Cycle 4 cycle , long still tolerate well . Temsirolimus give vein Days 1 , 8 , 15 cycle . During Day 1 Cycle 1 , receive 60 minute . If tolerate well Day 1 Cycle 1 , give 30 minute Days 8 15 Cycle 1 30 minute cycle , long still tolerate well . Everolimus work way show effective temsirolimus . Everolimus also give mouth , substitute temsirolimus . Everolimus take every day , start Day 1 Cycle 1 . Because nationwide shortage liposomal doxorubicin , may receive temsirolimus bevacizumab liposomal doxorubicin become available . If experience certain side effect , dose level may lower . In case , dose may stop 1 week , side effect get well . Your doctor explain detail , happen . Study Visits : During Cycle 1 , physical exam blood draw weekly ( 1 tablespoon ) routine test . For Cycle 2 cycle , physical exam blood drawn ( 1 tablespoon ) routine test every 3 week . The status disease check CT MRI scan every 2 cycle , Cycles 2-6 , every 2-3 cycle . Additional Procedures Some Participants : If group receive high safe dose study drug , follow additional procedure perform : - You biopsy performed end Cycle 1 . The biopsy use research see study drug combination act body learn may affect cancer cell . - You DCE-MRI scan 24-48 hour first study drug infusion ( Cycle 1 ) , end Cycle 1 . These DCE-MRI scan use research see study drug combination affect blood vessel supply nutrient oxygen tumor cell . Length Study Participation : You may continue receive additional cycle study drug , unless cancer go away completely , get bad , intolerable side effect occur . In case , take study . Long-Term Follow-Up : After last dose study drug , receive 3 phone call study staff . The call 1 month apart , ask . This investigational study . Liposomal doxorubicin , bevacizumab , temsirolimus commercially available . Liposomal doxorubicin FDA approve treatment multiple myeloma , ovarian cancer return , Kaposi 's sarcoma . Bevacizumab FDA approve treatment colorectal cancer type lung cancer . Temsirolimus FDA approve treatment kidney cancer spread . The combination liposomal doxorubicin , bevacizumab , temsirolimus FDA approve . At time , use research . Up 206 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients advance metastatic cancer refractory standard therapy , relapse standard therapy , standard therapy improve survival least three month . 2 . All patient must estimate life expectancy least 12 week . 3 . Patients must measurable evaluable disease 4 . Patients must previous chemotherapy radiotherapy three week prior enter study . Six week require patient received therapy know delayed toxicity ( mitomycin nitrosurea ) . Five halflives require biologic/targeted therapy short ( &lt; 24 hour ) halflives pharmacodynamic effect . Patients may receive palliative radiation immediately ( ) treatment provide radiation target lesion available . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 2 ( Karnofsky &gt; /= 60 % ) . 6 . Patients must organ marrow function define : absolute neutrophil count &gt; /= 1,500/mL ; platelet &gt; /=100,000/mL ; creatinine &lt; /= 3 X upper limit normal ( ULN ) ; total bilirubin &lt; /= 2.0 ; ALT ( SGPT ) &lt; /= 5 X ULN . In patient significant liver disease chronically elevate liver transaminase , ALT may elevate high 8 X ULN . 7 . Cardiac ejection fraction &gt; /= 50 % without evidence congestive heart failure ( CHF ) . 8 . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation , 90 day last dose . 9 . Ability understand willingness sign write informed consent document . 10 . Patients may receive investigational agent and/or concurrent anticancer agent therapy except hormonal maintenance treatment prostate cancer . 1 . Patients clinically significant unexplained bleeding within 28 day prior enter study 2 . Poorly control systemic vascular hypertension ( Systolic blood pressure &gt; 140 mmHg , diastolic blood pressure &gt; 90 mmHg ) 3 . Patients clinically significant cardiovascular disease : History cerebral vascular accident ( CVA ) within 6 month Myocardial infarction unstable angina within 6 month Unstable angina pectoris New York Heart Association Class CHF score â‰¥ II 4 . Prior cumulative doxorubicin dose &gt; 300 mg/m2 5 . Pregnant lactate woman 6 . History hypersensitivity doxil , doxorubicin , HCL , temsirolimus 's metabolite ( include sirolimus ) , polysorbate 80 , bevacizumab murine product 7 . Serious medical psychiatric illness likely interfere participation clinical study 8 . Patients &lt; 12 year age 9 . Inability swallow tablet everolimus arm .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Metastatic cancer</keyword>
	<keyword>Doxil</keyword>
	<keyword>Liposomal doxorubicin</keyword>
	<keyword>Doxorubicin hydrochloride ( liposomal )</keyword>
	<keyword>Avastin</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Anti-VEGF monoclonal antibody</keyword>
	<keyword>rhuMAb-VEGF</keyword>
	<keyword>Torisel</keyword>
	<keyword>Temsirolimus</keyword>
	<keyword>CCI-779</keyword>
	<keyword>Dynamic contrast-enhanced magnetic resonance imaging</keyword>
	<keyword>DCE-MRI scan</keyword>
</DOC>